Overview |
bsm-52052R |
Cytokeratin 10 (1D8) Monoclonal Antibody |
WB, IHC-P, IF(ICC) |
Human, Mouse, Rat |
Specifications |
Unconjugated |
Rabbit |
Recombinant human Cytokeratin 10 protein, around 150-250aa. |
Monoclonal |
1D8 |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
3858 |
P13645 |
BIE; EHK; K10; KPP; BCIE; CK10; Keratin, type I cytoskeletal 10; Cytokeratin-10; CK-10; Keratin-10; KRT10 |
Cytokeratin 10 is a heterotetramer of two type I and two type II keratins. Cytokeratin 10 is generally associated with keratin 1. It is seen in all suprabasal cell layers including stratum corneum. A number of alleles are known that mainly differ in the Gly-rich region (positions 490-560). Defects in cytokeratin 10 are a cause of epidermolytic hyperkeratosis (EHK), also known as bullous congenital ichthyosiform erythroderma (BCIE) or bullous erythroderma ichthyosiformis congenita of Brocq. EHK is an hereditary skin disorder characterized by blistering and a marked thickening of the stratum corneum. At birth, affected individuals usually present with redness, blisters and superficial erosions due to cytolysis. Within a few weeks, the erythroderma and blister formation diminish and hyperkeratoses develop. Transmission is autosomal dominant, but most cases are sporadic. Defects in cytokeratin 10 are also a cause of annular epidermolytic ichthyosis (AEI), also known as cyclic ichthyosis with epidermolytic hyperkeratosis. AEI resembles clinical and histologic features of both epidermolytic hyperkeratosis and ichthyosis bullosa of Siemens. |
Application Dilution |
WB |
1:300-5000 |
IHC-P |
1:200-400 |
IF(ICC) |
1:50-200 |